Neuronal nicotinic acetylcholine receptor alpha 7 (alpha7 nAChR) (alpha7 nAChR)

The neuronal nicotinic acetylcholine receptor alpha 7 (alpha7 nAChR) is a homopentameric ligand-gated ion channel primarily expressed in the central nervous system, particularly in the hippocampus and cerebral cortex (UniProt P36544; Wikipedia). It is distinguished by its high permeability to calcium and exceptionally rapid desensitization kinetics compared to other nicotinic subtypes (NIH, PMC4549060). Beyond its role in fast synaptic transmission and the modulation of neurotransmitter release (glutamate, GABA, dopamine), the alpha7 receptor is a key mediator of the cholinergic anti-inflammatory pathway, where its activation on macrophages inhibits the release of pro-inflammatory cytokines like TNF-alpha (NIH, PMC3683166). In disease states, alpha7 nAChR dysfunction is strongly associated with cognitive impairments in Alzheimer's disease and schizophrenia, as well as neurodegeneration in Parkinson's disease (NIH, PMC2854313). Therapeutic strategies focus on the development of agonists and positive allosteric modulators (PAMs) to enhance cognitive function and provide neuroprotection (NIH, PMC5647314). However, drug development faces significant challenges, including the receptor's rapid desensitization and the need for high subtype selectivity to avoid peripheral side effects such as the potential promotion of tumor growth or cardiovascular issues (NIH, PMC8406312).

Other names

CHRNA7alpha7 nAChRNeuronal acetylcholine receptor subunit alpha-7Cholinergic receptor nicotinic alpha 7 subunitnAChR alpha 7

The alpha7 nAChR is targeted by orthosteric agonists, partial agonists, and positive allosteric modulators (PAMs) to enhance its ionotropic (calcium influx) and metabotropic (JAK2/STAT3) signaling, while antagonists are primarily used as pharmacological tools to inhibit its activity.